Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valuing Drugs In The US: How We're Doing And What's Ahead

Executive Summary

Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.

You may also be interested in...



Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.

The Quality Lowdown: Foreign Burden, Border Destruction, Particles, Sterility

FDA asks about regulating foreign firms more and destroying drugs at the border, and questions firms about particles and aseptic practices.

One-Third Of Payers Preferred Biosimilars Over Reference Drug in 2017

As biosimilar uptake remains modest, rebate amounts trend upward for medical benefit drugs, according to latest MagellanRx drug trend report.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel